Member Info for bigAl67

Absolutely Eureka01 - ''Incognito the False'' owes you an Apology for calling you a liar - But ''Incognito the False'' has No Honour IMVHO - So I will apologise for him.

Eureka01

Posts: 44

Price: 21.00

No Opinion

RE: Eureka17 May 2023 09:29

No, Guy, my contact said that there would be an announcement on the day the public consultation began. As I said previously, it was MY assumption that this would be on the previously scheduled date and my apologies to all for that. I suppose a lesson that one must take nothing for granted!

As I Posted - ''Incognito the False'' - True ''Incognito Style''

Guy_incognito

Posts: 4,292

Price: 21.00

No Opinion

Eureka17 May 2023 07:11

Where is this GUARANTEED rns - Well it is here on the day that Eureka1 was told by the Company Rep it would be posted - The day that NICE open their Consultation period - And as explained by Eureka1 - Still No Apology from ''Incognito the False'' - Just dis-Honour by Deflection IMHO.

It has been stated that our CYP2C19 is still in Development All along!!!

A Reminder of the Quick to call Eureka1 a Liar Post:- Who is trying to Save Face Now - Not seen an Apology owed to Eureka1 ??

Guy_incognito

Posts: 4,291

Price: 21.00

No Opinion

RE: Eureka17 May 2023 09:01

Eureka01

Posted in: GDR

Posts: 43

Price: 22.50

No Opinion

RE: More Reasons to be Cheerful16 May 2023 07:47

Hmm, I see the same sceptics posting again. Yet previously my info, gleaned from the Company, was proved right. Most were expecting an RNS at the end of the NICE AIHL public consultation. I said it wouldn't happen and it didn't. Most were expecting an imminent RNS about the FDA pre submission discussions. I said it wouldn't happen and it didn't. Ok let's see what happens tomorrow. I have posted that there WILL BE an RNS

You said there would be an RNS today and your contact guaranteed it so you was lying , you are now trying to shift the goal posts

I wish you was right so the SP would increase , I’m not happy you are lying , just funny you are trying to save face after being caught out

Many Thanks to Eureka !!!!!!

Today 07:00

RNS Number : 9399Z

Genedrive PLC

19 May 2023

genedrive plc

("genedrive" or the "Company")

NICE recommends CYP2C19 genotyping for clopidogrel treatment

Genedrive® CYP2C19 ID test modelled to be a clinically and cost-effective option

Offer gene test to stroke patients, NHS told

Published

4 hours ago

People who have had a stroke caused by a blood clot should have a DNA test to see whether they can be given a drug to help prevent more brain attacks, new draft guidelines for the NHS say.

Stroke risk increases when someone has had one previously, which is why preventive medication is recommended.

But a standard anti-clot drug, clopidogrel, works well for patients with certain genes only.

Others need a different protective drug - so the gene check could save lives.

The blood or saliva test is quick and affordable.

Not you again Carlose666, thought I had got rid of the Bad Itch you bring to this Board, and that is all you bring - Posters just need to click on your Posting name, and read your Past 40+ posts, which All in their entirety attack Posters that dare post anything Positive.

As I Posted - ''Incognito the False'' - True ''Incognito Style''

Absolutely stephen11 - I Totally agree !!

LOL - ''Incognito the False'' weighing in now.

This is the ''Guy'' who Posted that he had averaged down to 32p, and was so Dis-gusted in our David Budd, that he could not wait to get out, once he was able to get his money back, he would be gone.

Well he has had several opportunities to allegedly get out, since making these statements, and in the 40's with an alleged Good Profit, But still posts his non-sence here, saying he is a Shareholder?

''Incognito style''

@Lloyd - You can weigh in all you like - You have no morality what so ever IMHO, when it comes to making/losing money.

I am a GDR Shareholder, and my sentiment has not changed ever since my first purchase - ''why'' - because I believe we will be successful with our AIHL Test, and other Products throughout the World, let alone in the UK and Europe - To the benefit of Both Patients and Shareholders !!

As Roger stated in his 2021 post it is not all about the money, ''as Great it will be to get back in profit'' - Roger posted some Very Strong Sentiment then towards posts that ignored what GDR are trying to do here - saving lives from a Life of Silence etc, and his disgust in Posters that did not recognise this (this would include you Lloyd IMHO) - How does this sort of sentiment change? - Ah - it is because it is about making a profit ''Quickly'' - The Quick Buck ideology?

I believe profit from GDR will come, and patients will benefit from our Products - just need to have patience, and not Betray/Disgust ourselves, along this journey.

And now we have our CYP2C19 to help others with too!!

Getting Medical Diagnostic Products into the Markets is not a quick and simple process, and when our SP gains good ascendancy again, sentiment will turn again.

@Roger,

Maybe you should take a leaf from your post:-

roger65

Posted in: GDR

Posts: 3,034

Price: 48.00

No Opinion

1 Sep 2021 01:05

excited

..to think GDR could quickly turn things around with the sp with some great reactions to AIHL. I'm fairly disgusted by the reaction of some posting here who can still only focus on money and their determined efforts to rubbish GDR and DB. I know I've hd my moments of feeling disillusioned but one should always stay alert to the possibility of circumstances changing or plain and simply getting it wrong. I still wouldn't be surprised if GDR suddenly received a take over offer but, regardless of that, I'm just delighted they have a product that will help the lives of many by avoiding a world without sound. This has to be applauded.

We are all here to make money but to constantly throw the human aspect of what GDR is trying to do with its products to one side in favour of profit/loss - and especially a product that is about to be successful - is extraordinary and appalling in equal measure. I've had my doubts over DB but AIHL and its imminent success must be lauded and I happily admit I may have got it terribly wrong on GDR and DB. Buying in at just shy of £1.50 and then finding yourself down by 65% doesn't make rational comment easy but ffs get a grip some of you and just be pleased GDR are going to change many lives from here on in for the better.

''The agreement puts the supply of our BioPlex pathogen detection assays through Mountain Horse, a military contracting specialist who has a number of existing framework contracts with target clients such as the U.S. DoD.  We believe that they have both the industry sector knowledge and existing commercial arrangements to increase the exposure of our products and gain new customer opportunities within the various branches and departments of the DoD and U.S. Government.”

 About Mountain Horse Solutions

Mountain Horse Solutions supplies rapid response customized equipment, systems, and training for infectious disease, security, technology, chemical, biological, radiological, nuclear, and explosive (CBRNE) hazards. We specially design innovative solutions to meet the individual unique threats, needs, and requirements of the military and first responders. Our team of professionals from around the globe has extensive experience with commercial, DOD, and U.S. Federal Government customers. Mountain Horse Solutions serves organizations, agencies, and contractors worldwide. To find out more visit: www.mtnhorse.com

Your post starres stated:-

''I think the most revenue they ever got was through US Department of Defense for the biological warfare test. (I reckon over £1m. at one stage. but not sure if Budd was in charge at that point. that opportunity just melted away in the end with no explanation)''

You made no mention of the agreement with Mountain Horse Solutions, in your post, and the context of your post reads that you are stating the opportunity of an order with the US Department of Defence melted away - my response is that the opportunity to get an order from the US Department of Defence did not just melt away, as it was always recognised that we developed the Test for the US Military of Defence because they wanted a secondary source Test, as a back up, should they need one, and that is what they have.

The Distribution agreement with Mountain Horse Solutions however gives us a wider market opportunity for our Biological Warfare Test:- It has not just melted away - Orders for Biological Warfare Tests do not come along as quick as orders for Cars - LOL

March 12, 2021, Colorado Springs, CO USA – Mountain Horse Solutions, a U.S. Defense and Mission Critical Equipment Supplier, announced it has entered into an exclusive agreement for distribution with genedrive plc (AIM:GDR), the near patient molecular diagnostic company from the United Kingdom. Mountain Horse will distribute genedrive’s Military Pathogen Detection assays in the United States.

Mountain Horse Solutions specializes in Chemical, Biological, Radiological, Nuclear, and Explosive (CBRNE) mission critical products and the genedrive BioPlex range of products are uniquely designed for military CBRNE requirements. Genedrive products were developed to the U.S. Department of Defence’s (U.S. DoD) product specification and using their targeted funding. Designed for field portability and rapid determination of biothreats from pathogens, the genedrive BioPlex system was developed over a period of five years and has been approved to deployment stage.

Mountain Horse’s track record of established local representation in the United States with  identified  U.S Government contracts in the highly specialized field of CBRNE partnered with genedrive’s world-class technology is a win-win relationship. Also, Mountain Horse Solutions holds existing framework purchasing agreements, providing an opportunity for more rapid order placement and replenishment of products without the need for new contracts to be negotiated.

 Bill Allen, President of Mountain Horse Solutions, said: “We are delighted to be working with genedrive with these exciting pathogen detection products.  This addition of genedrive’s assays to our portfolio of CBRNE mission critical products provides a unique offering of combat-ready sampling and detection devices.”

 David Budd, CEO of genedrive plc, said: “The agreeme

It was also explained that the US Department of Defence paid us to develop the Biological Test as a secondary source, should they need one - But starres is so desperate these days he has turned to posting his lies IMHO.

LOL - It was announced on the 16th November 2021, that Mathew Fowler was stepping down at Genedrive to join Music Magpie (mmag), and their SP was 163p on the 16th November 2021.

By the time Mathew Fowler left Genedrive to join MMAG, their SP had dropped to 45p - Not sure he read the 'reading on the wall', very accurately LOL.

Today mmag SP is 23.10p after hitting a low of 10.10p in November 2022.

Hi Eureka01,

Many Thanks for Posting, much appreciated!!

Positive final recommendation by NICE

30 Mar 2023 07:00

NICE's final EVA report can be accessed here:-

https://www.nice.org.uk/guidance/indevelopment/gid-hte10009/documents

Guidance published

Early Value Draft Guidance Consultation Document – Comments Theme: Recommendations

Comment:-

Would the EVA recommendation be, to include testing of all babies admitted to the NICU, rather than just those babies that are suspected to be at risk of infection or sepsis who need antibiotics? Please advise?

NICE Response:-

Thank you for your comment which NICE has considered.

The wording in recommendation 1.1 has now been updated to clarify that the recommendation applies to

newborns who are being considered for treatment with aminoglycosides. Please note the scope of the

assessment and recommendations are not limited to a neonatal intensive care unit (NICU) setting.

The EAG notes that the cost-effectiveness analysis was based on the babies needing antibiotics being tested and did not explore this. They would expect the testing to be less cost-effective if administered to all babies in the NICU rather than just those that are suspected to be at risk of infection and need antibiotics. However, this scenario was not explored in the analysis.

The committee noted that one of the centres in the PALOH study now routinely tests all babies on admission to the NICU. But it said that individual centres should decide which babies to test depending on local knowledge of what proportion of babies go on to receive aminoglycosides. Section 3.3 in the early value guidance document has been updated to reflect this.

Genedrive plc (AIM:GDR), the point of care molecular diagnostics company, announces that, further to the Company's announcement on 9 February 2023, the UK's National Institute for Health and Care Excellence (NICE) ''has today ratified and finalised its recommendation following a public consultation process that the Genedrive® MT-RNR1 ID Kit can be used by the NHS'' - '''Can be used by the NHS'''

Also:-

20 minutes into our 21st November 2022 Presentation David Budd did say that GDR are working with Independent Economic Modellers to develop a 'Spread sheet' or a 'straight forward analysis tool' that can illustrate very effectively the net savings to a Hospital, or a Hospital system or the NHS as a whole!!